Canaccord Genuity Reiterates a 'Buy' on AVEO Pharmaceuticals (AVEO); Rich Tivo Deal Validates Commercial Potential
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' on AVEO Pharmaceuticals (NASDAQ: AVEO), PT $23.
Canaccord analyst says, "Astellas’ attraction to tivozanib potential ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "Astellas’ attraction to tivozanib potential ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
